Avenzo Therapeutics to Participate at Upcoming Investor Conferences November 3rd, 2026|Business Wire| SAN DIEGO–(BUSINESS WIRE)–Avenzo Therapeutics to Participate at Upcoming Investor Conferences Please leave this field empty Subscribe to Our Newsletter We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information. Please check your Inbox or Spam folder now to confirm your subscription. Like this post? Share it! FacebookXLinkedInEmail Related Posts Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences November 10th, 2026 | 0 Comments Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights November 10th, 2026 | 0 Comments Immunome Reports Third Quarter 2026 Financial Results and Provides Business Update November 10th, 2026 | 0 Comments Genentech and Roche Present New Data Across Pharmaceuticals and Diagnostics From Its Growing Alzheimer’s Disease Portfolio at CTAD 2026 November 10th, 2026 | 0 Comments Neobe Raises $6.8 Million to Break Down the Barriers That Stop Cancer Treatments From Working November 10th, 2026 | 0 Comments Paysign Reports Record Third Quarter 2026 Revenue of $30.8 Million, Up 43%; Operating Margin More Than Triples to 23.8% November 9th, 2026 | 0 Comments Hims & Hers Health, Inc. Reports Third Quarter 2026 Financial Results November 9th, 2026 | 0 Comments AbCellera Reports Q3 2026 Business Results November 9th, 2026 | 0 Comments Dr. Andrew Huberman Joins Hims & Hers Board of Directors November 9th, 2026 | 0 Comments Myomo Reports Third Quarter 2026 Financial and Operating Results November 9th, 2026 | 0 Comments Community Health Systems Announces Proposed Exchange Offer and Consent Solicitation November 9th, 2026 | 0 Comments Bayer’s SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S. FDA to Reduce the Risk of Stroke in Adults With Recent Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack… November 9th, 2026 | 0 Comments